JP2023500337A5 - - Google Patents
Info
- Publication number
- JP2023500337A5 JP2023500337A5 JP2022525913A JP2022525913A JP2023500337A5 JP 2023500337 A5 JP2023500337 A5 JP 2023500337A5 JP 2022525913 A JP2022525913 A JP 2022525913A JP 2022525913 A JP2022525913 A JP 2022525913A JP 2023500337 A5 JP2023500337 A5 JP 2023500337A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- seq
- vaccine
- acid sequence
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930417P | 2019-11-04 | 2019-11-04 | |
| US62/930,417 | 2019-11-04 | ||
| US202062988102P | 2020-03-11 | 2020-03-11 | |
| US62/988,102 | 2020-03-11 | ||
| US202063018060P | 2020-04-30 | 2020-04-30 | |
| US63/018,060 | 2020-04-30 | ||
| US202063070987P | 2020-08-27 | 2020-08-27 | |
| US63/070,987 | 2020-08-27 | ||
| PCT/US2020/058891 WO2021092019A1 (en) | 2019-11-04 | 2020-11-04 | Combination therapy to treat brain cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002786A Division JP2026074006A (ja) | 2019-11-04 | 2026-01-09 | 脳がんを治療するための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500337A JP2023500337A (ja) | 2023-01-05 |
| JP2023500337A5 true JP2023500337A5 (enExample) | 2023-11-13 |
Family
ID=75686760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525913A Pending JP2023500337A (ja) | 2019-11-04 | 2020-11-04 | 脳がんを治療するための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210128710A1 (enExample) |
| EP (1) | EP4055033A4 (enExample) |
| JP (1) | JP2023500337A (enExample) |
| KR (1) | KR20220097928A (enExample) |
| CN (1) | CN114901677A (enExample) |
| AU (2) | AU2020380288B2 (enExample) |
| BR (1) | BR112022008164A2 (enExample) |
| CA (1) | CA3156227A1 (enExample) |
| CO (1) | CO2022007361A2 (enExample) |
| IL (1) | IL292462A (enExample) |
| MX (1) | MX2022005345A (enExample) |
| PH (1) | PH12022551078A1 (enExample) |
| WO (1) | WO2021092019A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12071633B2 (en) | 2020-10-13 | 2024-08-27 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
| CN113447654B (zh) * | 2021-07-15 | 2022-03-22 | 广州济士源生物技术有限公司 | 质谱技术检测尿液中psm-e分子水平在制备用于早期诊断前列腺癌产品中的应用 |
| IL310808A (en) * | 2021-08-13 | 2024-04-01 | Inovio Pharmaceuticals Inc | Combination therapy to treat brain cancer |
| US11526994B1 (en) * | 2021-09-10 | 2022-12-13 | Neosoma, Inc. | Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833754B2 (en) * | 2006-01-13 | 2010-11-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IL-12 for expression in mammalian cell |
| CN113684185A (zh) * | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US20190048085A1 (en) * | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| JP2019527737A (ja) * | 2016-08-09 | 2019-10-03 | アルケヤール， アルモハナッドＡＬＫＡＹＹＡＬ， Ａｌｍｏｈａｎａｄ | Ｉｌ１２を発現する腫瘍溶解性ラブドウイルス |
| EP3518955A4 (en) * | 2016-09-30 | 2020-10-07 | The Wistar Institute Of Anatomy And Biology | TERT-IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT THEREOF |
| EA201990624A1 (ru) * | 2017-03-07 | 2019-09-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Иммуногенные композиции tert и способы лечения с их использованием |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JP7216668B2 (ja) * | 2017-05-26 | 2023-02-01 | エピセントアールエックス，インコーポレイテッド | 導入遺伝子を保持する組換えアデノウイルス |
| CN109486828B (zh) * | 2018-12-27 | 2022-05-31 | 广东暨大基因药物工程研究中心有限公司 | 一种编码重组人白细胞介素12的基因及其应用 |
| EP3969040A1 (en) * | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| WO2021051065A1 (en) * | 2019-09-12 | 2021-03-18 | Inovio Pharmaceuticals, Inc. | Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same |
| JP2022552748A (ja) * | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
-
2020
- 2020-11-04 AU AU2020380288A patent/AU2020380288B2/en active Active
- 2020-11-04 MX MX2022005345A patent/MX2022005345A/es unknown
- 2020-11-04 CN CN202080088086.1A patent/CN114901677A/zh active Pending
- 2020-11-04 WO PCT/US2020/058891 patent/WO2021092019A1/en not_active Ceased
- 2020-11-04 JP JP2022525913A patent/JP2023500337A/ja active Pending
- 2020-11-04 IL IL292462A patent/IL292462A/en unknown
- 2020-11-04 CA CA3156227A patent/CA3156227A1/en active Pending
- 2020-11-04 EP EP20884253.4A patent/EP4055033A4/en active Pending
- 2020-11-04 PH PH1/2022/551078A patent/PH12022551078A1/en unknown
- 2020-11-04 BR BR112022008164A patent/BR112022008164A2/pt unknown
- 2020-11-04 US US17/089,244 patent/US20210128710A1/en active Pending
- 2020-11-04 KR KR1020227018389A patent/KR20220097928A/ko active Pending
-
2022
- 2022-05-27 CO CONC2022/0007361A patent/CO2022007361A2/es unknown
-
2024
- 2024-04-30 AU AU2024202791A patent/AU2024202791A1/en active Pending